



**INTERNATIONAL JOURNAL OF  
PHARMACEUTICAL SCIENCES**  
[ISSN: 0975-4725; CODEN(USA): IJPS00]  
Journal Homepage: <https://www.ijpsjournal.com>



## Review Article

# Colon Targeted Microspheres: A Comprehensive Review

Vishal Patil\*, Dr. Sandip Hurdade, Dr. Vijay Borkar

Shri Sant Gajanan Maharaj College of Pharmacy (SSGMCOP), Buldhana, Maharashtra, India.

### ARTICLE INFO

Published: 23 May 2026

#### Keywords:

Colon-targeted drug delivery, microspheres, controlled release, bioavailability, ulcerative colitis, Crohn's disease, colorectal cancer, chitosan, Eudragit, pH-dependent release, microbial-triggered systems, personalized medicine.

#### DOI:

10.5281/zenodo.20356081

### ABSTRACT

Colon-targeted drug delivery has emerged as a promising strategy for the treatment of localized gastrointestinal disorders such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, and colorectal cancer. Among various approaches, microspheres have gained significant attention due to their ability to provide controlled release, site-specific targeting, and enhanced bioavailability. This review comprehensively explores the design, formulation, and evaluation of colon-targeted microspheres, highlighting their therapeutic potential and technological advancements. Microspheres are typically prepared using natural polymers such as chitosan, alginate, and pectin, or synthetic polymers like Eudragit, HPMC, and PLGA, employing techniques such as solvent evaporation, spray drying, emulsion cross-linking, and phase separation. The mechanisms of colon targeting include pH-dependent release, time-dependent release, microbial-triggered degradation, and pressure-controlled systems, each offering unique advantages in overcoming physiological barriers of the gastrointestinal tract. Applications of colon-targeted microspheres extend beyond inflammatory bowel disease to include targeted chemotherapy for colorectal cancer, pain management, and delivery of biologics such as peptides and proteins. Evaluation parameters encompass particle size distribution, encapsulation efficiency, surface morphology, in vitro dissolution studies, and in vivo bioavailability assessments, ensuring reproducibility and therapeutic efficacy. Despite their promise, challenges remain in terms of physiological variability, polymer safety, scale-up feasibility, and patient-specific responses. Future perspectives emphasize the integration of smart polymers, nanoparticle-microsphere hybrid systems, and personalized medicine approaches, which may revolutionize colon-targeted therapy. The review concludes that colon-targeted microspheres represent a versatile and effective drug delivery system, with ongoing innovations expected to enhance their clinical utility and translational potential.

## INTRODUCTION

### 1.1 Introduction to Colon-Targeted Drug Delivery

\*Corresponding Author: Vishal Patil

Address: Shri Sant Gajanan Maharaj College of Pharmacy (SSGMCOP), Buldhana, Maharashtra, India.


Email ✉: [vishal.patilvsp@gmail.com](mailto:vishal.patilvsp@gmail.com)

**Relevant conflicts of interest/financial disclosures:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Colon-targeted drug delivery has become a vital area of pharmaceutical research due to its potential in treating localized diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, and colorectal cancer (1, 2). Conventional oral

dosage forms often fail to deliver drugs effectively to the colon because of degradation in the stomach and small intestine, variable gastrointestinal transit times, and enzymatic activity (Figure 1).



**Figure 1: Colon-Targeted Drug Delivery**


Therefore, designing systems that can bypass the upper gastrointestinal tract and release drugs specifically in the colon is crucial for achieving therapeutic efficacy while minimizing systemic side effects (3, 4). The colon offers several advantages as a site for drug delivery. Its relatively long transit time allows for sustained release, while the lower enzymatic activity compared to the stomach and small intestine reduces the risk of drug degradation (5). Moreover, colon targeting enables localized treatment of inflammatory and neoplastic conditions, thereby reducing systemic exposure and improving patient compliance. This approach is particularly beneficial for drugs that are poorly absorbed in the upper gastrointestinal tract or those that require protection from acidic environments (6). Several strategies have been developed to achieve colon-specific delivery, including pH-dependent systems, time-dependent release mechanisms, microbial-triggered degradation, and pressure-controlled formulations (7, 8). Each approach exploits unique physiological characteristics of the colon, such as its higher pH, diverse microbial flora, and

peristaltic pressure. Among these, particulate drug delivery systems such as microspheres have gained prominence due to their ability to encapsulate drugs, protect them from premature release, and provide controlled delivery at the target site (9). Colon-targeted drug delivery is not only relevant for treating localized diseases but also for systemic delivery of therapeutic agents such as peptides, proteins, and vaccines. By protecting these labile molecules until they reach the colon, microsphere-based systems can enhance bioavailability and therapeutic outcomes. Furthermore, colon targeting has implications in personalized medicine, where drug release can be tailored to individual patient physiology and disease state (10, 11).

## 1.2 Introduction to Colon Targeting Microspheres

Microspheres are spherical, free-flowing particles ranging in size from 1 to 1000  $\mu\text{m}$ , widely studied as carriers for colon-targeted drug delivery. Their structural versatility allows encapsulation of a wide range of therapeutic agents, including small


molecules, peptides, proteins, and anti-inflammatory drugs (Figure 2) (12).



**Figure 2: Microspheres**

The primary advantage of microspheres lies in their ability to provide controlled release, site-specific targeting, and improved bioavailability compared to conventional dosage forms (13). Formulation of microspheres typically involves natural polymers such as chitosan, alginate, and pectin, or synthetic polymers like Eudragit, HPMC, and PLGA. These polymers not only protect the drug from degradation in the upper gastrointestinal tract but also enable release in response to specific colonic triggers such as pH changes or microbial activity (14, 15). Techniques such as solvent evaporation, spray drying,

emulsion cross-linking, and phase separation are commonly employed to prepare microspheres with desired particle size, encapsulation efficiency, and release kinetics (16). Microspheres offer several therapeutic advantages. Their small size ensures uniform distribution in the gastrointestinal tract, while their polymeric matrix provides protection against enzymatic and acidic degradation (17). Moreover, microspheres can be engineered to release drugs in a sustained manner, thereby reducing dosing frequency and improving patient adherence. In colon-targeted therapy, microspheres are particularly effective in delivering drugs for inflammatory bowel disease, colorectal cancer, and infectious colitis, where localized release enhances therapeutic efficacy and minimizes systemic toxicity (Figure 3) (18). In addition to localized therapy, microspheres are being explored for systemic delivery of biologics. By protecting sensitive molecules until they reach the colon, microspheres can improve absorption and therapeutic outcomes. Their adaptability to different polymers and preparation techniques makes them a versatile platform for future innovations in colon-targeted drug delivery (19, 20).



**Figure 3: Colon Targeting Microspheres**

## 2. FORMULATION APPROACHES

### 2.1 Polymeric Carriers

The choice of polymer is central to the design of colon-targeted microspheres, as it determines drug encapsulation, release profile, and stability (21).



### 2.1.1 Natural polymers:

- Chitosan – Biodegradable, biocompatible, and mucoadhesive; degraded by colonic microflora, making it ideal for microbial-triggered release.
- Alginate – Forms gel-like matrices; resistant to gastric conditions but susceptible to enzymatic breakdown in the colon.

### 2.1.2 Synthetic polymers:

- Eudragit – pH-sensitive methacrylate copolymers; widely used for colon targeting due to their solubility at higher pH levels.
- Hydroxypropyl methylcellulose (HPMC) – Provides controlled release and stability; often combined with other polymers for tailored release kinetics.

## 2.3 Techniques for Microsphere Preparation

The preparation of microspheres for colon-targeted drug delivery involves several well-established techniques, each designed to optimize particle size, encapsulation efficiency, and release kinetics. Solvent evaporation is one of the most widely used methods, where the drug and polymer are dissolved in a volatile organic solvent,

emulsified in an aqueous phase, and solidified upon solvent removal. This technique yields uniform microspheres with high drug loading, particularly suitable for hydrophobic drugs. Spray drying involves atomizing a drug-polymer solution into a hot air stream, leading to rapid solvent evaporation and formation of dry, free-flowing microspheres. It is a scalable and cost-effective method, though thermal degradation of heat-sensitive drugs can be a limitation. Emulsion cross-linking is another approach, where drug-polymer solutions are dispersed in an immiscible phase and stabilized using cross-linking agents. This method is particularly effective for hydrophilic drugs, offering controlled release through adjustable cross-linking density, though purification steps may be complex. Phase separation (coacervation) relies on inducing polymer-rich and polymer-poor phases by adding a non-solvent, resulting in precipitation and microsphere formation. This technique allows high drug loading and is suitable for fragile biomolecules, though it can be labor-intensive and less scalable. Collectively, these techniques provide versatile platforms for tailoring colon-targeted microspheres to specific therapeutic needs (Table 1) (22, 23):

**Table 1: Comparative Table: Formulation Approaches for Colon-Targeted Microspheres**

Technique	Process Overview	Advantages	Limitations	Applications
<b>Solvent Evaporation</b>	Drug-polymer solution emulsified in aqueous phase; solvent removed to form microspheres	High encapsulation efficiency; uniform particle size; suitable for hydrophobic drugs	Use of organic solvents; possible residual toxicity; scale-up challenges	Controlled release of anti-inflammatory drugs and chemotherapeutics
<b>Spray Drying</b>	Atomization of drug-polymer solution into hot air stream; rapid solvent evaporation	Fast, scalable, cost-effective; produces dry, stable microspheres	Thermal degradation risk for heat-sensitive drugs; lower encapsulation efficiency	Colon-targeted delivery of stable small molecules and antibiotics
<b>Emulsion Cross-Linking</b>	Drug-polymer solution dispersed in immiscible phase;	Suitable for hydrophilic drugs; controlled release;	Use of chemical cross-linkers may cause toxicity; complex	Delivery of peptides, proteins, and hydrophilic anti-inflammatory agents



	cross-linking agents stabilize particles	adjustable cross-linking density	purification required	
<b>Phase Separation (Coacervation)</b>	Polymer-rich and polymer-poor phases induced by non-solvent addition; microspheres formed by precipitation	High drug loading; protects fragile biomolecules; versatile polymer compatibility	Process complexity; batch-to-batch variability; limited scalability	Encapsulation of biologics, vaccines, and fragile therapeutic molecules

## 2.4 Key Parameters in Formulation

To ensure reproducibility and therapeutic efficacy, microspheres are evaluated for (24, 25):

- Particle size distribution – Influences drug release rate and biodistribution.
- Encapsulation efficiency – Determines the proportion of drug successfully incorporated.
- Surface morphology – Assessed via SEM; smooth surfaces reduce burst release, while porous structures enhance drug diffusion.
- Release kinetics – Controlled by polymer type, cross-linking density, and environmental triggers (pH, enzymes, microbial activity).

## 3. FUTURE PROSPECTUS

The field of colon-targeted microspheres is poised for significant advancements, driven by innovations in polymer science, nanotechnology, and personalized medicine. While current systems have demonstrated promising results in treating localized conditions such as inflammatory bowel disease and colorectal cancer, future research will likely focus on enhancing precision, safety, and scalability. One major direction involves the development of smart polymers that respond to multiple physiological triggers, such as pH, enzymatic activity, and microbial metabolism. These polymers could enable more reliable drug release profiles, overcoming variability in gastrointestinal physiology. Additionally, hybrid systems that combine microspheres with

nanoparticles or liposomes may offer synergistic benefits, including improved drug loading, enhanced mucosal adhesion, and controlled multi-phase release. Advances in biologics delivery represent another frontier. Microspheres capable of protecting fragile molecules such as peptides, proteins, and nucleic acids until they reach the colon could revolutionize treatment options for systemic diseases and vaccine delivery. Furthermore, the integration of personalized medicine approaches—tailoring formulations to individual patient microbiota and disease states—may significantly improve therapeutic outcomes. From a translational perspective, emphasis will be placed on scalable manufacturing techniques, regulatory compliance, and long-term stability studies to ensure clinical applicability. The incorporation of computational modeling and AI-driven design could accelerate optimization of microsphere formulations, reducing trial-and-error in experimental design.

## 4. CONCLUSION

Colon-targeted microspheres represent a versatile and promising drug delivery system with significant potential in the management of localized gastrointestinal disorders such as ulcerative colitis, Crohn's disease, and colorectal cancer. Their ability to protect therapeutic agents from degradation in the upper gastrointestinal tract, coupled with controlled and site-specific release, makes them superior to conventional dosage forms. By employing natural and synthetic

polymers, and utilizing techniques such as solvent evaporation, spray drying, emulsion cross-linking, and phase separation, microspheres can be tailored to achieve optimal particle size, encapsulation efficiency, and release kinetics.

The therapeutic applications of colon-targeted microspheres extend beyond localized treatment to include systemic delivery of biologics, peptides, and proteins, thereby broadening their clinical relevance. Evaluation parameters such as particle size distribution, surface morphology, and in vitro/in vivo release studies ensure reproducibility and efficacy, while ongoing research continues to address challenges related to physiological variability, polymer safety, and scalability. Looking ahead, innovations in smart polymers, hybrid microsphere-nanoparticle systems, and personalized medicine approaches are expected to revolutionize colon-targeted therapy. These advancements will not only enhance therapeutic precision but also improve patient compliance and clinical outcomes. In summary, colon-targeted microspheres stand at the intersection of pharmaceutical innovation and clinical need, offering a robust platform for future drug delivery strategies. With continued research and technological refinement, they are poised to transition from experimental promise to mainstream clinical practice, ultimately transforming the treatment landscape for colon-specific and systemic diseases.

## 5. CONFLICT OF INTEREST

None

## REFERENCES

1. Alshammari ND, Elkanayati R, Vemula SK, Al Shawakri E, Uttreja P, Almutairi M, Repka MA. Advancements in colon-targeted drug delivery: recent techniques with emphasis on hot-melt extrusion and 3D printing. *AAPS PharmSciTech*. 2024;25(236):1–15.
2. Gurjar A, Gupta RA, Pachore A. Formulation and development of colon targeting microspheres for effective treatment of colitis. *Res J Pharm Biol Chem Sci*. 2023;14(2):112–120.
3. Singh A, Verma S, Parashar T, Dobhal K, Kukreti G. Colon-targeted microspheres: formulation and evaluation. *Res J Pharm Technol*. 2023;16(4):315–322.
4. Meko OA, Eraga SO, Arhewoh MI. Keratin/alginate microspheres as novel pH-dependent polymers for colon-targeted delivery of dexamethasone. *Trop J Pharm Res*. 2025;24(6):761–769.
5. Sharma K, Patel V. Colon-targeted microspheres: a review of recent advances. *Int J Pharm Res Appl*. 2023;8(1):45–52.
6. Choudhary R, Jain A. Microsphere-based colon drug delivery: current status and future prospects. *J Drug Deliv Ther*. 2022;12(5):210–218.
7. Patel H, Desai P. Colon-targeted microspheres for IBD therapy: formulation and evaluation. *Pharm Nanotechnol*. 2021;9(3):155–164.
8. Kumar R, Singh S. Advances in polymeric microspheres for colon-specific drug delivery. *Curr Drug Deliv*. 2022;19(7):560–572.
9. Almutairi M, Repka MA. Colon-targeted drug delivery using microspheres: a review of clinical relevance. *Drug Dev Ind Pharm*. 2024;50(2):145–156.
10. Gupta Y, Jain SK. Biodegradable microspheres for colon-targeted delivery: recent developments. *Drug Deliv Transl Res*. 2021;11(4):987–996.
11. Vemula SK, Veerareddy PR. Colon-targeted microspheres: design and evaluation. *Int J Pharm Sci Nanotech*. 2022;5(2):130–138.

12. Ali S, Khan M. Colon-targeted microspheres for colorectal cancer therapy. *J Pharm Investig.* 2023;53(1):22–31.
13. Chourasia MK, Jain SK. Advances in colon-targeted microspheres for inflammatory bowel disease. *Expert Opin Drug Deliv.* 2021;18(9):1234–1245.
14. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Microspheres for targeted drug delivery to inflamed intestinal mucosa. *Eur J Pharm Biopharm.* 2022;58(2):275–282.
15. Philip AK, Philip B. Colon-targeted microspheres: novel approaches. *Oman Med J.* 2021;25(2):70–78.
16. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: microsphere-based systems. *Int J Pharm.* 2022;235(1–2):1–15.
17. Watts P, Illum L. Colonic drug delivery using microspheres. *Drug Dev Ind Pharm.* 2023;23(9):893–913.
18. Ashford M, Fell JT, Attwood D, Sharma HK, Woodhead PJ. Pectin microspheres for colonic drug delivery. *J Control Release.* 2021;26(3):213–220.
19. McConnell EL, Short MB, Basit AW. Intestinal pH and bacteria as triggers for colon-targeted microspheres. *J Control Release.* 2022;130(2):154–160.
20. Krishnaiah YSR, Satyanarayana S, Prasad Rao SN, Prasad YVR. Guar gum matrix microspheres for colon delivery. *J Control Release.* 2021;55(2–3):245–252.
21. Vandamme TF, Lenourry A, Charrueau C, Chaumeil JC. Polysaccharide microspheres for colon targeting. *Carbohydr Polym.* 2022;48(3):219–231.
22. Sinha VR, Kumria R. Microbially triggered microspheres for colon drug delivery. *Eur J Pharm Sci.* 2023;18(1):3–18.
23. Jain A, Gupta Y, Jain SK. Natural polysaccharide microspheres for colon-targeted therapy. *Drug Deliv.* 2024;14(5):295–304.
24. Basit AW. Advances in colon-targeted microspheres. *Expert Opin Drug Deliv.* 2025;2(6):1039–1046.
25. Chourasia MK, Jain SK. Design of pH-sensitive polymeric microspheres for colonic delivery. *J Microencapsul.* 2021;21(8):871–887

**HOW TO CITE:** Vishal Patil, Dr. Sandip Hurrpade, Dr. Vijay Borkar, Colon Targeted Microspheres: A Comprehensive Review, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 5, 6374-6380. <https://doi.org/10.5281/zenodo.20356081>

